Waltz Comments on CMS Blanket Waivers of Hospital Stay Requirements Amid COVID-19 Pandemic
23 March 2020
Report on Medicare Compliance
Partner Judith Waltz was quoted in the Report on Medicare Compliance article, “COVID-19 Waivers: Some SNFs Refuse Hospital Patients Anyway, MA Coverage is Better” about CMS’ blanket waiver of hospital stay requirements during the COVID-19 pandemic as a way to free up hospital beds.
The blanket waivers for excluded-part units are based on cost-report categories, Waltz said. “This gives hospitals flexibility to use the space without worrying about the cost-report implications.”
Waltz added that the waivers for skilled nursing facilities are heartfelt. “This is a recognition that the beneficiaries are suffering,” she said. Waltz said she understands, however, that given their vulnerability, skilled nursing facilities may hope patients complete three-day in hospital stays prior to be transferred to their facilities and are in better shape by the time they get there.
Waltz is the co-chair of Foley’s Health Care Industry Team.
(Subscription required)
People
Related News
26 September 2024
In the News
Gregory Marino on NIL Litigation – 'Schools want to know where the line is, and now everything is in flux'
Foley & Lardner LLP special counsel Gregory Marino shared insight on the growing complexities of collegiate sports in the ABA Journal article, "Money and litigation tangle with recent rules for college athletes' NIL deals."
24 September 2024
In the News
Thomas Ferrante Assesses Recent HHS OIG Report on Remote Patient Monitoring
Foley & Lardner LLP partner Thomas Ferrante commented on the recently released report on remote patient monitoring from the U.S. Department of Health and Human Services Office of Inspector General (OIG) in the Fierce Healthcare article, “HHS watchdog flags potential remote monitoring fraud. Stakeholders say concerns about misuse are overblown.”
20 September 2024
In the News
David Rosen Featured for Insight on Looming FDA Final Rule for Cosmetic Manufacturing
Foley & Lardner LLP partner David Rosen is featured by CosmeticsDesign for his insights on the U.S. Food and Drug Administration's final rule establishing Good Manufacturing Practices for the cosmetics industry in the article, "Preparing for MoCRA’s 2025 cGMP deadline: What cosmetic manufacturers and suppliers need to know."